Jason James joined Currax Pharmaceuticals LLC in 2022 as VP, Finance, Commercial Operations, and Analytics, bringing with him over 20 years of proven leadership in finance, commercial and digital analytics, machine learning, and statistics in healthcare.

Prior to joining Currax Pharmaceuticals, Jason served as VP of Commercial Operations for Cognoa, a software as medical device (SaMD) start-up with June 2021 FDA authorization for an Autism Spectrum Disorder machine learning-enabled digital diagnostic aid. There, he established the core commercial infrastructure and the go-to-market playbook inclusive of core field sales processes, sales operations, business analytics, payor segmentation, coding and reimbursement strategy. Previously, Jason served as VP of Business Analytics and Operations for Zealand Pharma, where he was one of the first U.S. commercial leadership hires for this Denmark-headquartered peptide development leader, reporting to the U.S. President.

Earlier positions include serving as VP of Global Business Analytics and Sales Operations for Avexis, Inc. (acquired by Novartis), and SVP of Commercial Operations and Analytics for Catalyst Pharmaceuticals, where he established the pre-and post-launch analytics strategy and commercial infrastructure supporting the successful launch of FIRDAPSE®, with over $100M in revenue in its first year and 400 patients enrolled. Additional roles include Group VP of Corporate Analytics for Horizon Pharma, and Finance, Analytics, Forecasting and Commercial Assessment senior roles at Lundbeck and Abbott Laboratories.

Jason received his Bachelor of Science in Finance from the Indiana University Kelley School of Business, and his Master of Professional Studies in Analytics from Northeastern University.